CLINICAL STUDIES
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation
Alexandre Abizaid, MDa,
Ran Kornowski, MDa,
Gary S. Mintz, MD, FACCa,
Mun K. Hong, MD, FACCa,
Andrea S. Abizaid, MDa,
Roxana Mehran, MDa,
Augusto D. Pichard, MD, FACCa,
Kenneth M. Kent, MD, PhD, FACCa,
Lowell F. Satler, MD, FACCa,
Hongsheng Wu, PhDa,
Jeffrey J. Popma, MD, FACCa and
Martin B. Leon, MD, FACCa
a Cardiac Catheterization Laboratories, The Washington Hospital Center, Washington, DC, USA
Manuscript received February 19, 1998;
revised manuscript received May 13, 1998,
accepted May 20, 1998.
Address for correspondence: Martin B. Leon, MD, Director, Cardiovascular Research, Washington Cardiology Center, 110 Irving Street NW, Suite 4B1, Washington, DC 20010
MBL1{at}mhg.edu
 |
Abstract
|
|---|
Objectives. We compared the clinical outcomes following coronary stent implantation in insulin-treated diabetes mellitus (IDDM), non-IDDM patients, and nondiabetic patients.
Background. Diabetic patients have increased restenosis and late morbidity following balloon angioplasty. The impact of diabetes mellitus (DM), especially IDDM, on in-stent restenosis is not known.
Methods. We studied 954 consecutive patients with native coronary artery lesions treated with elective Palmaz-Schatz stents implantation using conventional coronary angiographic and intravascular ultrasound methodology. Procedural success, major in-hospital complications, and 1-year clinical outcome were compared according to the diabetic status.
Results. In-hospital mortality was 2% in IDDM, significantly higher (p <0.02) compared with non-IDDM (0%) and nondiabetics (0.3%). Stent thrombosis did not differ among groups (0.9% in IDDM vs. 0% in non-IDDM and 0% in nondiabetics, p >0.1). During follow-up, target lesion revascularization (TLR) was 28% in IDDM, significantly higher (p <0.05) compared with non-IDDM (17.6%) and nondiabetics (16.3%). Late cardiac event–free survival (including death, myocardial infarction [MI], and any coronary revascularization procedure) was significantly lower (p = 0.0004) in IDDM (60%) compared with non-IDDM (70%) and nondiabetic patients (76%). By multivariate analysis, IDDM was an independent predictor for any late cardiac event (OR = 2.05, p = 0.0002) in general and TLR (odds ratio = 2.51, p = 0.0001) in particular.
Conclusions. In a large consecutive series of patients treated by elective stent implantation, IDDM patients were at higher risk for in-hospital mortality and subsequent TLR and, as a result, had a significantly lower cardiac event–free survival rate. On the other hand, acute and long-term procedural outcome was found to be similar for non-IDDM compared with nondiabetic patients.
|
Abbreviations and Acronyms
| | CSA | = cross-sectional area | | CSN | = cross-sectional narrowing | | EEM | = external elastic membrane | | IDDM | = insulin-dependent diabetes mellitus | | IVUS | = intravascular ultrasound | | MLD | = minimum lumen diameter | | P + M | = plaque + media | | PTCA | = balloon angioplasty | | TLR | = target lesion revascularization |
|
Diabetic patients have an increased risk of restenosis after balloon angioplasty (PTCA) (1–10), resulting in increased late morbidity and mortality compared with nondiabetic patients. Recently, intracoronary stents have been shown to improve procedural outcome and decrease restenosis in focal, de novo native coronary lesions compared with PTCA (11,12). However, even with stents, diabetic patients seem to have increased late loss index and restenosis compared with nondiabetic patients (13,14), although stents may still improve results compared with PTCA in diabetic patients (15,16). Furthermore, in the stent era few studies have examined the acute procedural and long-term outcome of insulin-dependent diabetes mellitus (IDDM) and non–insulin-dependent diabetes mellitus (non-IDDM) versus nondiabetic patients following coronary interventions.
The purpose of the current study was to determine the influence of IDDM and non-IDDM on in-hospital and long-term outcomes following stent implantation in native coronary arteries. We compared in-hospital results and 1-year clinical outcome in diabetics compared with a concurrent series of nondiabetic patients.
|
Methods
|
|---|
Study population.
The patient cohort includes a consecutive series of 954 patients (1,304 lesions) in the Cardiology Research Foundation Angioplasty Database, treated with Palmaz-Schatz stents (Cordis) in native coronary arteries between January 1994 and January 1996. Patients were divided into three groups according to their diabetic status. There were 706 (74%) patients without diabetes, 151 (15.8%) diabetic patients treated with oral hypoglycemic drugs (non-IDDM), and 97 (10.2%) diabetic patients treated with insulin (IDDM). Indications included planned elective stent use and planned provisional stent implantation use following a suboptimal result with a nonstent balloon or other primary device. Patients were excluded from the current analysis if they were treated by Gianturco-Rubin stents, investigational (non–FDA-approved) stents, if the stents were implanted for bail-out indications or to treat saphenous vein graft lesions, or if stent implantation was preceded by atheroablative device use.
Baseline clinical demographics and in-hospital events were confirmed by independent hospital chart review. Long-term outcome data were obtained by serial telephone interviews conducted by research nurses. Late clinical events (death, nonfatal myocardial infarction, and any revascularization) and target lesion revascularization (TLR) were adjudicated and corroborated by primary source documentation. All patients were treated and studied after giving informed consent. These protocols have the ongoing approval of the Washington Hospital Center Institutional Review Board.
Stent implantation techniques.
Details of the stent implantation procedure have been previously described (11,12). Following the initial balloon angioplasty, coronary or "biliary" Palmaz-Schatz stents were implanted over a 0.014-in. guidewire. Coronary stents were used whenever possible; the larger "biliary" version was reserved for vessels  4 mm in diameter. Adjunct high-pressure PTCA was performed after initial stent deployment (routinely to 16 atmospheres) in all cases. Angiographic and intravascular ultrasound (IVUS) assessment was obtained pretreatment, post–stent implantation, and post–adjunct PTCA. IVUS was performed at all time points in 94% of cases. Optimal stent implantation was carefully monitored using an interactive technique with prespecified IVUS endpoints and additional high-pressure inflations as needed. IVUS was used to optimize stent apposition, expansion (defined as minimal stent area 80% of the average of the proximal and distal references lumen area), and lesion coverage. In addition, IVUS enabled the detection of inflow-outflow obstruction and residual dissection at both stent margins. The poststent anticoagulation regimens included aspirin (325 mg/d) and ticlopidine (250 mg BID for 1 month) for all patients. Low molecular weight heparin (for 2 weeks) was administered in particularly high-risk patients (usually patients treated with 3 stents).
Angiographic analysis.
Cineangiograms were reviewed by our Angiographic Core Laboratory at the Washington Hospital Center by an observer unaware of the clinical outcome. Standard morphologic criteria were used for the identification of lesion location, length ("shoulder-to-shoulder"), eccentricity, irregularity, fluoroscopic calcification, and ulceration.
Quantitative angiographic analysis was performed using selected end-diastolic cineframes demonstrating the stenosis in its most severe and nonforeshortened projection. Cineframes were optically magnified (2.4:1) and digitized using a cine-video converter. Using the contrast-filled guiding catheter as the calibration standard, reference and minimal lumen diameters (MLD) were determined before and after stent implantation, and post–final adjunct PTCA using a validated, automated edge-detection algorithm (Cardiovascular Measurement Systems; Medis). Based upon these measurements, percent diameter stenoses were determined.
IVUS analysis.
IVUS studies were performed using a commercially available system (Boston Scientific Corporation/Cardio Vascular Imaging System, Inc.). This system incorporated a single-element 30-MHz transducer mounted on the tip of a flexible drive shaft within a 3.2-F short monorail polyethylene imaging sheath. The transducer was rotated 1800 rpm to form planar images in real time and withdrawn mechanically at 0.5 mm/s with a motorized transducer pullback device to perform the imaging sequence. IVUS studies were recorded on 0.5-in. high-resolution s-VHS tapes for off-line analysis. To perform the imaging sequence, the imaging catheter was advanced approximately 10 mm distal to the lesion, the motorized transducer pullback device was activated, and a complete uninterrupted imaging run was performed back to the aorto-ostial junction.
Cross-sectional measurements of external elastic membrane (EEM), stent, lumen, and plaque + media (P + M) cross-sectional areas (CSA) by IVUS have been validated (17,18). The term EEM is short-hand for the media-adventitia border, which is a reproducible measure of the total arterial CSA. Because media thickness cannot be measured accurately, P + M CSA was used as a measure of the amount of atherosclerotic plaque. The term cross-sectional narrowing (CSN) has also been called the plaque burden or percent plaque area by other investigators. When the tissue encompassed the catheter, the lumen was assumed to be the physical (not acoustical) size of the imaging catheter. Therefore, 1.0 mm was the smallest MLD and 0.8 mm2 was the smallest lumen CSA that could be measured preintervention.
Using computerized planimetry (TapeMeasure; Indec Systems, Inc.), the target lesion was assessed preintervention by measuring: (1) EEM CSA (mm2); (2) lumen CSA (mm2); (3) MLD (mm); (4) P + M CSA (mm2, equals EEM CSA minus lumen CSA); and (5) CSN (%, equals P + M CSA divided by EEM CSA). The target lesion was also assessed postintervention. Final IVUS measurements included: (1) stent CSA (mm2), (2) lumen CSA (mm2), and (3) MLD (mm).
The target lesion was normalized for the reference segment. Reference segment dimensions were calculated as the mean of the proximal and distal reference. Each reference segment was selected as the most normal-looking cross section within 10 mm proximal or distal to the target lesion, but before a major side branch. If either the proximal or distal reference segment could not be analyzed (e.g., ostial lesion location, diffuse disease, or major side branch close to the lesion), then only one reference segment measurement was used.
Statistics.
Statistical analysis was performed using SAS software (19). Continuous variables are presented as mean ± 1 standard deviation. Categorical data are presented as percent frequency and compared between groups using chi-square statistics. Multivariate analysis was performed by SAS (SAS Institute) Logistic Regression Statistics. Survival curves were calculated and displayed using the SAS LIFETEST procedure. The Wilcoxon test was used for survival comparison between groups (IDDM vs. non-IDDM vs. nondiabetics). The means of nominal values were compared using analysis of variances (ANOVA). A p value <0.05 was considered as statistically significant.
|
Results
|
|---|
Demographics.
Table 1
lists the baseline characteristics of all treated patients, grouped according to the diabetic status. Overall, demographics in patients with non-IDDM and nondiabetics were similar. Patients with IDDM were more often female (50.5%), hypertensive (73.3%), and had a previous CABG surgery (32.6%) (p <0.05 compared with the other two groups). Left ventricular ejection fraction was similar for all three groups. The average number of stents per procedure was not different among the three groups (1.9 ± 1.0, 2.2 ± 1.5, and 1.8 ± 1.0 in nondiabetic, non-IDDM, and IDDM patients, respectively, p >0.1).
Qualitative and quantitative angiographic results (Tables 2 and 3).
Lesion location was similar among the groups. Likewise, the qualitative lesion characteristics were also similar among the groups. Quantitative measurements preprocedure showed that the reference vessel size was smaller in the IDDM group compared with nondiabetics; however, postprocedure measurements were similar in all three groups.
IVUS analysis (Tables 4 and 5).
IVUS measurements preintervention were similar among the three groups, except for EEM at the lesion site, which was significantly smaller in the IDDM group compared with the other two groups.
Postintervention, the instent lumen area and minimum lumen diameter were significantly smaller in the IDDM group compared with the other two groups.
In-hospital events (Table 6).
Overall procedural success (<50% final diameter stenosis and TIMI flow >3 without major in-hospital complications) was uniformly high: 97.2% for IDDM, 96.8% for non-IDDM, and 98.3% for nondiabetic patients (p >0.1). Similarly, combined major in-hospital complications (death, Q-wave myocardial infarction, and emergent coronary artery bypass surgery) did not differ significantly among the groups. However, in-hospital mortality was 2.0% in IDDM, significantly higher compared with 0% in non-IDDM and 0.3% in nondiabetics (p <0.05 for each comparison). Subacute stent thrombosis was less than 1% and did not differ significantly among the three groups.
Long-term outcomes (Table 7).
One-year clinical follow-up was available in 950 of 954 (99.6%) patients. The overall coronary event rate (death, nonfatal myocardial infarction, TLR, and any revascularization) during follow-up was higher in IDDM (39.8%) compared with non-IDDM and nondiabetic patients (p <0.05). There was no statistically significant difference in either death or nonfatal myocardial infarction among the groups. TLR was 28% in IDDM, significantly higher compared with 17.6% in non-IDDM and 16.3% in nondiabetics (p <0.05 for each comparison). Moreover, revascularization procedures (TLR and non–TLR-related procedure) were more common in IDDM (37.6%), compared with non-IDDM (28.2%) and nondiabetics (22.7%) (p <0.05 for each comparison). Actuarial event-free survival curves for any coronary event are shown in Figure 1. Coronary event–free survival at 1 year was 60% in IDDM, significantly lower compared with 70% in non-IDDM and 76% in nondiabetics (p = 0.0004). Similarly, TLR-free survival (Fig. 2) was significantly lower in IDDM, compared with the other two groups (p = 0.0001).
Multivariate analysis.
Logistic regression analysis was used to identify the independent predictors of any adverse cardiac event and TLR at 1 year of follow-up. IDDM (OR = 2.05, p = 0.0002), QCA final procedural MLD (OR = 0.44, p = 0.01), and IVUS reference site plaque + media CSA (OR = 1.24, p = 0.01) were found to predict any adverse event at 1 year. IDDM (OR = 2.51, p = 0.0001), final procedural MLD by QCA (OR = 0.47, p = 0.023), IVUS final minimum lumen CSA (OR = 0.72, p = 0.013), IVUS preprocedural reference lumen CSA (OR = 0.57, p = 0.011), and IVUS preprocedure lesion site plaque + media (OR = 2.04, p = 0.003) were found to predict TLR at 1 year.
|
Discussion
|
|---|
In this large consecutive series of patients treated with IVUS-guided elective stent implantation in native coronary arteries, IDDM patients had worse procedural and long-term clinical outcomes compared with non-IDDM or nondiabetic patients. In this study, patients with IDDM (compared with non-IDDM and nondiabetic patients) manifested: (1) higher in-hospital mortality; (2) higher cardiac event rate during 1-year follow-up, which is primarily due to more coronary revascularization procedures (both TLR and non-TLR); and (3) significantly lower event-free survival. Importantly, IDDM was found to be an independent predictor for coronary events and TLR during follow-up. Conversely, after coronary stenting, non-IDDM patients had a similar in-hospital mortality and late TLR compared with nondiabetic patients. Nevertheless, overall event-free survival for non-IDDM patients was lower than nondiabetic patients, primarily due to more non-TLR revascularization procedures (10.6%) from progression of disease in untreated sites. By multivariate analysis, we identified independent clinical, angiographic, and IVUS predictors of future clinical events. These predictors were IDDM, final MLD by QCA, and IVUS plaque + media at the reference sites. The independent predictors of TLR were final MLD by QCA, final IVUS lumen CSA, and preprocedure plaque + media at lesion site.
PTCA in diabetic patients.
The role of DM as a clinical predictor for an adverse procedural outcome and higher restenosis rate after PTCA has been well documented (1–10). Prior to the stent era, these studies reported restenosis rates of 47–71% after PTCA among diabetic patients, compared with 30–40% in nondiabetics. The majority of these studies did not distinguish between IDDM patients versus non-IDDM. Stein et al. (10) were the only investigators who distinguished between IDDM and non-IDDM. They reported that IDDM patients had similar procedural results, but worse long-term outcome compared with non-IDDM. These data strongly indicate that restenosis and progression of coronary disease are more frequent among diabetic patients. More recently, the Emory experience has found that at 5 and 10 years, IDDM patients had lower survival rates after balloon PTCA compared with to the entire diabetic population (72% and 31% vs. 78% and 45%, respectively) (20). A recent subanalysis of The Bypass Angioplasty Revascularization Investigation (BARI) Trial revealed a worse 5-year survival rate in diabetic patients with multivessel coronary disease treated by balloon angioplasty compared with coronary bypass surgery (21). These findings highlighted again the problem of managing DM patients by the transcatheter interventional approach.
Stent treatment in diabetic patients.
Carrozza et al. (13) found increased late loss and a greater incidence of restenosis among diabetics after coronary stenting compared with nondiabetics (55% vs. 20%, p = 0.001). This study had a relatively small number of diabetic patients (37 patients), the majority of whom (70%) were non-IDDM. Furthermore, 54% of the lesions were in saphenous vein grafts. Thus, although this study indicated that diabetics had a higher restenosis rate, it could not distinguish between IDDM and non-IDDM, and suggested that intimal hyperplasia is more abundant in DM within the stented site. A recent subanalysis of the STRESS trial revealed a significant decrease in restenosis among DM patients treated by stents implantation compared with balloon angioplasty (24% vs. 60%, p <0.001), suggesting a major benefit for stents among DM patients (15). Likewise, Van Belle et al. found a lower angiographic restenosis rate in diabetic patients who were treated with stents compared with those treated with balloon angioplasty (25% vs. 63%) (16). In the same study, the restenosis rates were similar in diabetics and nondiabetics treated with stents (25% vs. 27%, respectively). In none of these studies was there a distinction between IDDM and non-IDDM patients.
Mechanisms for restenosis in DM.
Recent serial (postintervention and follow-up) IVUS observations from our laboratory have demonstrated the cause for increased restenosis in DM (22). It was found that diabetic patients manifested an increased proliferative response after transcatheter coronary interventions in both stented and nonstented lesions. Because of small patient numbers, no distinction could be made between IDDM and non-IDDM patients.
The distinction between IDDM and non-IDDM patients became apparent from recent pre-intervention IVUS observations: there were major differences in lesion and reference vessel adaptive remodeling characteristics in IDDM patients versus non-IDDM and nondiabetic patients (23). According to these IVUS findings, coronary atherosclerosis in patients with IDDM manifested as smaller vessels; there was less atherosclerotic plaque burden and less positive remodeling for a given degree of plaque accumulation. These lesion site characteristics might attenuate the benefit of coronary stenting in IDDM patients. Because of the smaller EEM dimensions, contemporary stenting (maximizing balloon to artery ratio and high pressure balloon expansion) might exaggerate vascular injury and hence evoke a more aggressive proliferative response within coronary stents among IDDM patients. Moreover, final stent CSA was smaller in IDDM patients compared with their counterparts. This variable was also found to be an independent predictor for TLR in the multivariate model.
Excessive neointimal reaction in diabetes probably resulted from complex hormonal and biochemical alterations associated with DM in general and with insulin treatment in particular (24). These might result in accelerated smooth muscle cell proliferation after coronary stenting (25–27). Experimental studies have found that vascular smooth muscle cells are sensitive to the growth stimulatory action of insulin and insulin-like growth factors (25–27). Insulin therapy may elevate the vascular sympathetic tone (28). In addition, the proatherogenic effect of insulin therapy might be responsible for accelerated atherosclerosis in untreated less severe lesions, resulting in more non-TLR interventions in IDDM patients (29,30).
Study limitations.
This was a retrospective analysis of the clinical, angiographic, and IVUS data derived from a large group of consecutively studied patients with careful and nearly complete follow-up data. The relatively small group of IDDM patients analyzed may have resulted in Type II statistical errors when comparing the clinical outcome to those in non-IDDM and non-DM groups.
Differences in baseline demographics and lesion characteristics could have produced the current findings. For example, lesions in smaller vessels containing unfavorable plaque morphology might result in unfavorable stent treatment results. However, angiographic morphology and lesion location in the IDDM patients were similar to those in the other two groups.
Although, in our study, insulin treatment was found to predict unfavorable clinical outcomes after stenting, insulin use may be a surrogate rather than a cause of such adverse outcomes. Insulin-treated patients might be at more advanced stage of coronary atherosclerosis and therefore more prone to cardiovascular complications.
Conclusions.
In a large consecutive series of patients treated with stent implantation, IDDM patients had higher in-hospital mortality and morbidity and increased 1-year coronary event rates following the procedure. Consequently, a significantly lower event-free survival was found in IDDM compared with non-IDDM and non-DM patients. By contrast, non-IDDM patients have a similar procedural success and long-term TLR compared with nondiabetic patients. Stents appear to equalize procedural results and TLR events for non-IDDM patients (compared with nondiabetics), but IDDM patients are still at increased risk for acute and long-term adverse outcomes.
|
Footnotes
|
|---|
This study was supported in part by the Cardiology Research Foundation, Washington, DC.
|
References
|
|---|
1. Holmes DR Jr, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984;53:77C–81C[CrossRef][Medline]
2. Myler RK, Topol EJ, Shaw RE, et al. Multiple vessel coronary angioplasty: classification, results, and patterns of restenosis in 494 consecutive patients. Cathet Cardiovasc Diagn. 1987;13:1–15[Medline]
3. Vandormeal MG, Deligonul U, Kern MJ, et al. Multilesion coronary angioplasty: clinical and angiographic follow-up. J Am Coll Cardiol. 1987;10:246–252[Abstract]
4. Hollman J, Badhwar K, Beck GJ, Granco I, Simpfendorfer C. Risk factors for recurrent stenosis following successful coronary angioplasty. Clev Clin J Med. 1989;56:517–523[Medline]
5. Quigley PJ, Hlatky MA, Hinohara T, et al. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent stenosis. Am J Cardiol. 1989;63:409–413[CrossRef][Medline]
6. Deligonul U, Vandormeal M, Kern MJ, Galan KL. Repeat coronary angioplasty and predictors of recurrent stenosis. Am J Cardiol. 1989;117:997–1002
7. Lambert M, Bonan R, Cote G, et al. Multiple coronary angioplasty: a model to discriminate systemic and procedural factors related to restenosis. J Am Coll Cardiol. 1988;12:310–314[Abstract]
8. Weintraub ES, Kosinski AS, Brown CL, King SB. Can restenosis after coronary angioplasty be predicted from clinical variables. J Am Coll Cardiol. 1993;21:6–14[Abstract]
9. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Curier JW. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996;94:1818–1825[Abstract/Free Full Text]
10. Stein B, Weintraub WS, Gebhart SSP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transmural coronary angioplasty. Circulation. 1995;91:979–989[Abstract/Free Full Text]
11. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501[CrossRef][Medline]
12. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–495[CrossRef][Medline]
13. Carrozza JP, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med. 1993;118:344–349[Abstract/Free Full Text]
14. Elezi S, Schuhlen H, Wehinger A, et al. Stent placement in diabetic versus non-diabetic patients: Six-month angiographic follow-up. J Am Coll Cardiol. 1997;29(Suppl A):188
15. Savage MP, Fischman DL, Slota P, et al. Coronary intervention in the diabetic patient: improved outcome following stent implantation versus balloon angioplasty. J Am Coll Cardiol. 1997;29(Suppl A):188
16. Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: A comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation. 1997;96:1454–1460[Abstract/Free Full Text]
17. Tobis JM, Mallery J, Mahon D, et al. Intravascular ultrasound imaging of human coronary arteries in vivo; analysis of tissue characteristics with comparison to in vivo histologic specimens. Circulation. 1991;83:913–926[Abstract/Free Full Text]
18. Potkin BN, Bartorelli AL, Gessert JM, et al. Coronary artery imaging with intravascular high-frequency ultrasound. Circulation. 1990;81:1575–1585[Abstract/Free Full Text]
19. Ray AA. SAS User’s Guide. Cary, NC: SAS Institute, 1986.
20. Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol. 1998;31:10–19[Abstract/Free Full Text]
21. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217–225[CrossRef][Medline]
22. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia: A serial intravascular study. Circulation. 1997;95:1366–1369[Abstract/Free Full Text]
23. Kornowski R, Mintz GS, Lansky AH, et al. Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am J Cardiol. 1998;81:1298–1304[CrossRef][Medline]
24. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996;27:528–535[Abstract]
25. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cell. Circ Res. 1975;36:319–327[Abstract/Free Full Text]
26. Pfefile B, Ditschuneit H. Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologica. 1981;20:155–158[CrossRef][Medline]
27. Bornfeldt KE, Raines EW, Nakano T, Graves TN, Krebs EG, Ross R. Insulin like growth factor-1 and platelet derived growth factors-BB induce direct migration of human smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest. 1994;93:1266–1274[Medline]
28. Baron AD. Hemodynamic action of insulin. Am J Physiol. 1994;267:E187–E202[Medline]
29. Reaven GM. The role of insulin resistance and hyperinsulinemia in coronary artery disease. Metabolism. 1992;41(Suppl 1):16–19[CrossRef][Medline]
30. Sobel BE. Potentiation of vasculopathy by insulin. Circulation. 1996;93:1613–1615[Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, S.-J. Kang, K.-S. Rhee, J.-K. Chae, J.-K. Ko, et al.
A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus: 4-Year Clinical Outcomes of DES-DIABETES (Drug-Eluting Stent in patients with DIABETES mellitus) Trial
J. Am. Coll. Cardiol. Intv.,
March 1, 2011;
4(3):
310 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Rana, L. Venkitachalam, F. Selzer, S. R. Mulukutla, O. C. Marroquin, W. K. Laskey, E. M. Holper, V. S. Srinivas, K. E. Kip, S. F. Kelsey, et al.
Evolution of Percutaneous Coronary Intervention in Patients with Diabetes: A report from the National Heart, Lung, and Blood Institute-sponsored PTCA (1985-1986) and Dynamic (1997-2006) Registries
Diabetes Care,
September 1, 2010;
33(9):
1976 - 1982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Wolf, H. A. Vlachos, O. C. Marroquin, J. S. Lee, C. Smith, W. D. Anderson, J. T. Schindler, E. M. Holper, J. D. Abbott, D. O. Williams, et al.
Paclitaxel-Eluting Versus Sirolimus-Eluting Stents in Diabetes Mellitus: A Report From the National Heart, Lung, and Blood Institute Dynamic Registry
Circ Cardiovasc Interv,
February 1, 2010;
3(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Leigh Perkins
Preclinical Models of Restenosis and Their Application in the Evaluation of Drug-Eluting Stent Systems
Veterinary Pathology,
January 1, 2010;
47(1):
58 - 76.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Otake, Y. Honda, and P. J. Fitzgerald
Chapter 10 The role of intravascular ultrasound in percutaneous coronary intervention
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Kapur and A. Qureshi
Chapter 21 Revascularization in diabetes mellitus
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Takagi, H. Okura, Y. Kobayashi, T. Kataoka, H. Taguchi, I. Toda, K. Tamita, A. Yamamuro, Y. Sakanoue, A. Ito, et al.
A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
524 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Qiangjun Cai, K. Skelding, A. Armstrong Jr, D. Desai, G. C. Wood, and J. Blankenship
Predictors of Long-Term Major Adverse Cardiac Events and Clinical Restenosis Following Elective Percutaneous Coronary Stenting
Angiology,
April 1, 2009;
60(2):
141 - 147.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al.
TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program
J. Am. Coll. Cardiol. Intv.,
March 1, 2009;
2(3):
240 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B Lindsey, F. Cipollone, S. M Abdullah, and D. K Mcguire
Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications
Diabetes and Vascular Disease Research,
January 1, 2009;
6(1):
7 - 14.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Jimenez-Quevedo, N. Suzuki, C. Corros, C. Ferrer, D. J. Angiolillo, F. Alfonso, R. Hernandez-Antolin, C. Banuelos, J. Escaned, C. Fernandez, et al.
Vessel Shrinkage as a Sign of Atherosclerosis Progression in Type 2 Diabetes: A Serial Intravascular Ultrasound Analysis
Diabetes,
January 1, 2009;
58(1):
209 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. O. Jensen, M. Maeng, P. Thayssen, E. H. Christiansen, K. N. Hansen, A. Galloe, H. Kelbaek, J. F. Lassen, and L. Thuesen
Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial
Eur. Heart J.,
November 2, 2008;
29(22):
2733 - 2741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al.
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad
Eur. Heart J.,
July 2, 2008;
29(14):
1729 - 1738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Billinger, J. Beutler, K. R. Taghetchian, A. Remondino, P. Wenaweser, S. Cook, M. Togni, C. Seiler, C. Stettler, F. R. Eberli, et al.
Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients
Eur. Heart J.,
March 2, 2008;
29(6):
718 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ortolani, M. Balducelli, P. Marzaroli, G. Piovaccari, A. Menozzi, V. Guiducci, P. Sangiorgio, F. Tarantino, G. Geraci, F. Castriota, et al.
Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions: Results From a Real-World Multicenter Registry
Circulation,
February 19, 2008;
117(7):
923 - 930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Mulukutla, H. A. Vlachos, O. C. Marroquin, F. Selzer, E. M. Holper, J. D. Abbott, W. K. Laskey, D. O. Williams, C. Smith, W. D. Anderson, et al.
Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients A Report from the NHLBI Dynamic Registry.
J. Am. Coll. Cardiol. Intv.,
January 1, 2008;
1:
139 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-C. Fang, Yeun Tarl Fresner Ng Jao, Yi-Chen, C.-L. Yu, C.-L. Chen, and S.-P. Wang
Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience
Angiology,
November 1, 2007;
58(5):
523 - 534.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Baumgart, V. Klauss, F. Baer, F. Hartmann, H. Drexler, W. Motz, H. Klues, S. Hofmann, W. Volker, T. Pfannebecker, et al.
One-Year Results of the SCORPIUS Study: A German Multicenter Investigation on the Effectiveness of Sirolimus-Eluting Stents in Diabetic Patients
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1627 - 1634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, E. Bernardo, C. Ramirez, M. A. Costa, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al.
Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment
J. Am. Coll. Cardiol.,
July 18, 2006;
48(2):
298 - 304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A K Mitra and D K Agrawal
In stent restenosis: bane of the stent era.
J. Clin. Pathol.,
March 1, 2006;
59(3):
232 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Lauruschkat, B. Arnrich, A. A. Albert, J. A. Walter, B. Amann, U. P. Rosendahl, T. Alexander, and J. Ennker
Prevalence and Risks of Undiagnosed Diabetes Mellitus in Patients Undergoing Coronary Artery Bypass Grafting
Circulation,
October 18, 2005;
112(16):
2397 - 2402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al.
Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment
Diabetes,
August 1, 2005;
54(8):
2430 - 2435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Hermiller, A. Raizner, L. Cannon, P. A. Gurbel, M. A. Kutcher, S. C. Wong, M. E. Russell, S. G. Ellis, R. Mehran, G. W. Stone, et al.
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1172 - 1179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J.,
April 2, 2005;
26(8):
804 - 847.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Finn, I. F. Palacios, A. Kastrati, and H. K. Gold
Drug-eluting stents for diabetes mellitus: A rush to judgment?
J. Am. Coll. Cardiol.,
February 15, 2005;
45(4):
479 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Briguori, G. Condorelli, F. Airoldi, F. Manganelli, A. Violante, A. Focaccio, B. Ricciardelli, and A. Colombo
Impact of microvascular complications on outcome after coronary stent implantations in patients with diabetes
J. Am. Coll. Cardiol.,
February 1, 2005;
45(3):
464 - 466.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Briguori, G Condorelli, F Airoldi, G W Mikhail, B Ricciardelli, and A Colombo
Impact of glycaemic and lipid control on outcome after percutaneous coronary interventions in diabetic patients
Heart,
December 1, 2004;
90(12):
1481 - 1482.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. A. Fonseca, J. Diez, and D. B. McNamara
Decreasing Restenosis Following Angioplasty: The potential of peroxisome proliferator-activated receptor {gamma} agonists
Diabetes Care,
November 1, 2004;
27(11):
2764 - 2766.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Naka, L. G. Bucciarelli, T. Wendt, L. K. Lee, L. L. Rong, R. Ramasamy, S. F. Yan, and A. M. Schmidt
RAGE Axis: Animal Models and Novel Insights Into the Vascular Complications of Diabetes
Arterioscler Thromb Vasc Biol,
August 1, 2004;
24(8):
1342 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Moussa, M. B. Leon, D. S. Baim, W. W. O'Neill, J. J. Popma, M. Buchbinder, J. Midwall, C. A. Simonton, E. Keim, P. Wang, et al.
Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy
Circulation,
May 18, 2004;
109(19):
2273 - 2278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-F. Yan, R. Ramasamy, L. G Bucciarelli, T. Wendt, L. K Lee, B. I Hudson, D. M Stenr, E. Lalla, S. Du Yan, L. L. Rong, et al.
RAGE and its ligands: a lasting memory in diabetic complications?
Diabetes and Vascular Disease Research,
May 1, 2004;
1(1):
10 - 20.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. M. Dewey, K. Crumrine, M. A. Herbert, A. Leonard, S. L. Prince, C. Worley, J. R. Edgerton, M. J. Magee, and M. J. Mack
First-year outcomes of beating heart coronary artery bypass grafting using proximal mechanical connectors
Ann. Thorac. Surg.,
May 1, 2004;
77(5):
1542 - 1549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Wilson, B. A. Vakili, W. Sherman, T. A. Sanborn, and D. L. Brown
Effect of Diabetes on Long-Term Mortality Following Contemporary Percutaneous Coronary Intervention: Analysis of 4,284 cases
Diabetes Care,
May 1, 2004;
27(5):
1137 - 1142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mehran, G. D. Dangas, Y. Kobayashi, A. J. Lansky, G. S. Mintz, E. D. Aymong, M. Fahy, J. W. Moses, G. W. Stone, and M. B. Leon
Short- and long-term results after multivessel stenting in diabetic patients
J. Am. Coll. Cardiol.,
April 21, 2004;
43(8):
1348 - 1354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Gilbert, J. Raboud, and B. Zinman
Meta-Analysis of the Effect of Diabetes on Restenosis Rates Among Patients Receiving Coronary Angioplasty Stenting
Diabetes Care,
April 1, 2004;
27(4):
990 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Chaves, A. G.M.R. Sousa, L. A. Mattos, A. Abizaid, R. Staico, F. Feres, M. Centemero, L. F. Tanajura, A. Abizaid, I. Pinto, et al.
Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab: Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial
Circulation,
February 24, 2004;
109(7):
861 - 866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E.J. West, P. N. Ruygrok, C. M.C. Disco, M. W.I. Webster, W. K. Lindeboom, W. W. O'Neill, N. F. Mercado, and P. W. Serruys
Clinical and Angiographic Predictors of Restenosis After Stent Deployment in Diabetic Patients
Circulation,
February 24, 2004;
109(7):
867 - 873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Corpus, P. B. George, J. A. House, S. R. Dixon, S. C. Ajluni, W. H. Devlin, G. C. Timmis, M. Balasubramaniam, and W. W. O'Neill
Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention
J. Am. Coll. Cardiol.,
January 7, 2004;
43(1):
8 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kornowski and S. Fuchs
Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions
J. Am. Coll. Cardiol.,
January 7, 2004;
43(1):
15 - 17.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Abizaid, M. A. Costa, D. Blanchard, M. Albertal, H. Eltchaninoff, G. Guagliumi, L. Geert-Jan, A. S. Abizaid, A. G.M.R. Sousa, E. Wuelfert, et al.
Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: Insights from the RAVEL Trial
Eur. Heart J.,
January 2, 2004;
25(2):
107 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. F. Yan, R. Ramasamy, Y. Naka, and A. M. Schmidt
Glycation, Inflammation, and RAGE: A Scaffold for the Macrovascular Complications of Diabetes and Beyond
Circ. Res.,
December 12, 2003;
93(12):
1159 - 1169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehilli, A. Kastrati, H. Bollwein, A. Dibra, H. Schuhlen, J. Dirschinger, and A. Schomig
Gender and restenosis after coronary artery stenting
Eur. Heart J.,
August 2, 2003;
24(16):
1523 - 1530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Bhargava, G. Karthikeyan, A. S Abizaid, and R. Mehran
New approaches to preventing restenosis
BMJ,
July 31, 2003;
327(7409):
274 - 279.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-H. Mak and D. P. Faxon
Clinical studies on coronary revascularization in patients with type 2 diabetes
Eur. Heart J.,
June 2, 2003;
24(12):
1087 - 1103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Lincoff
Important Triad in Cardiovascular Medicine: Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Receptor Blockade
Circulation,
March 25, 2003;
107(11):
1556 - 1559.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Mooradian
Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines
Arch Intern Med,
January 13, 2003;
163(1):
33 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Cole, E. L. Jones, J. M. Craver, R. A. Guyton, D. C. Morris, J. S. Douglas Jr, Z. Ghazzal, and W. S. Weintraub
Outcomes of repeat revascularization in diabetic patients with prior coronary surgery
J. Am. Coll. Cardiol.,
December 4, 2002;
40(11):
1968 - 1975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Sedlis, D. A. Morrison, J. D. Lorin, R. Esposito, G. Sethi, J. Sacks, W. Henderson, F. Grover, K. B. Ramanathan, D. Weiman, et al.
Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry
J. Am. Coll. Cardiol.,
November 6, 2002;
40(9):
1555 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Popma, M. Suntharalingam, A. J. Lansky, R. R. Heuser, B. Speiser, P. S. Teirstein, V. Massullo, T. Bass, R. Henderson, S. Silber, et al.
Randomized Trial of 90Sr/90Y {beta}-Radiation Versus Placebo Control for Treatment of In-Stent Restenosis
Circulation,
August 27, 2002;
106(9):
1090 - 1096.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Van Belle, M. Perie, D. Braune, A. Chmait, T. Meurice, K. Abolmaali, E. P. McFadden, C. Bauters, J.-M. Lablanche, and M. E. Bertrand
effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients
J. Am. Coll. Cardiol.,
August 7, 2002;
40(3):
410 - 417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Mathew and D. R. Holmes
Outcomes in diabetics undergoing revascularization: The long and the short of it
J. Am. Coll. Cardiol.,
August 7, 2002;
40(3):
424 - 427.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Gruberg, R. Waksman, A. E. Ajani, H.-S. Kim, R. L. White, E. E. Pinnow, L. F. Satler, A. D. Pichard, K. M. Kent, and J. Lindsay Jr
The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus
J. Am. Coll. Cardiol.,
June 19, 2002;
39(12):
1930 - 1936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Beckman, M. A. Creager, and P. Libby
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
JAMA,
May 15, 2002;
287(19):
2570 - 2581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. O. Bonow, W. E. Mitch, R. W. Nesto, P. T. O'Gara, R. C. Becker, L. T. Clark, S. Hunt, I. Jialal, S. E. Lipshultz, and E. Loh
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group V: Management of Cardiovascular-Renal Complications
Circulation,
May 7, 2002;
105(18):
e159 - e164.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Lowe, S. N. Oesterle, and L. M. Khachigian
Coronary in-stent restenosis: Current status and future strategies
J. Am. Coll. Cardiol.,
January 16, 2002;
39(2):
183 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hase, N. Joki, M. Nakamura, T. Tsunoda, Y. Tanaka, M. Fukazawa, Y. Takahashi, Y. Imamura, R. Nakamura, and T. Yamaguchi
Favourable long-term outcome by repeated percutaneous coronary revascularization in diabetic haemodialysis patients
Nephrol. Dial. Transplant.,
January 1, 2002;
17(1):
100 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Erdmann
Cardiovascular events in patients with type 2 diabetes
The British Journal of Diabetes & Vascular Disease,
January 1, 2002;
2(1_suppl):
S4 - S8.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. J. Th. Wackers and B. L. Zaret
Detection of Myocardial Ischemia in Patients With Diabetes Mellitus
Circulation,
January 1, 2002;
105(1):
5 - 7.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Abizaid, M. A. Costa, M. Centemero, A. S. Abizaid, V. M.G. Legrand, R. V. Limet, G. Schuler, F. W. Mohr, W. Lindeboom, A. G.M.R. Sousa, et al.
Clinical and Economic Impact of Diabetes Mellitus on Percutaneous and Surgical Treatment of Multivessel Coronary Disease Patients: Insights From the Arterial Revascularization Therapy Study (ARTS) Trial
Circulation,
July 31, 2001;
104(5):
533 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. King III
Coronary artery bypass graft or percutaneous coronary interventions in patients with diabetes: another nail in the coffin or "too close to call?"
J. Am. Coll. Cardiol.,
March 15, 2001;
37(4):
1016 - 1018.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hoffmann and G.S. Mintz
Coronary in-stent restenosis--predictors, treatment and prevention
Eur. Heart J.,
November 1, 2000;
21(21):
1739 - 1749.
[PDF]
|
|
|
|
|
|
|
J. M. Ahmed, M. K. Hong, R. Mehran, G. Dangas, G. S. Mintz, A. D. Pichard, L. F. Satler, K. M. Kent, H. Wu, G. W. Stone, et al.
Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting
J. Am. Coll. Cardiol.,
October 1, 2000;
36(4):
1186 - 1193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hammoud, J.-F. Tanguay, and M. G. Bourassa
Management of coronary artery disease: therapeutic options in patients with diabetes
J. Am. Coll. Cardiol.,
August 1, 2000;
36(2):
355 - 365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hasdai, C. B. Granger, S. S. Srivatsa, D. A. Criger, S. G. Ellis, R. M. Califf, E. J. Topol, and D. R. Holmes Jr.
Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy
J. Am. Coll. Cardiol.,
May 1, 2000;
35(6):
1502 - 1512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Schofer, M. Schluter, T. Rau, F. Hammer, N. Haag, and D. G. Mathey
Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study
J. Am. Coll. Cardiol.,
May 1, 2000;
35(6):
1554 - 1559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Bhatt, S. P. Marso, A. M. Lincoff, K. E. Wolski, S. G. Ellis, and E. J. Topol
Abciximab reduces mortality in diabetics following percutaneous coronary intervention
J. Am. Coll. Cardiol.,
March 15, 2000;
35(4):
922 - 928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. King III and E. Mahmud
Will Blocking the Platelet Save the Diabetic?
Circulation,
December 21, 1999;
100(25):
2466 - 2468.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Marso, A. M. Lincoff, S. G. Ellis, D. L. Bhatt, J.-F. Tanguay, N. S. Kleiman, T. Hammoud, J. E. Booth, S. K. Sapp, and E. J. Topol
Optimizing the Percutaneous Interventional Outcomes for Patients With Diabetes Mellitus : Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) Diabetic Substudy
Circulation,
December 21, 1999;
100(25):
2477 - 2484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mehran, G. Dangas, A. S. Abizaid, G. S. Mintz, A. J. Lansky, L. F. Satler, A. D. Pichard, K. M. Kent, G. W. Stone, and M. B. Leon
Angiographic Patterns of In-Stent Restenosis : Classification and Implications for Long-Term Outcome
Circulation,
November 2, 1999;
100(18):
1872 - 1878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Worse Stent Outcome in Insulin-Dependent Diabetics
Journal Watch Cardiology,
October 9, 1998;
1998(1009):
6 - 6.
[Full Text]
|
|
|
|
Top
Abstract
Methods
